Under a three-year agreement, South African firm NeoGenesis will commercialize products containing the PS128® strain in South Africa. It is the second time in less than 1 month that Bened signs an agreement on PS128® for a value of at least 6 figures USD.
‘The agreement allows PS128® to now be available in Africa, in addition to Asia, Europe and America’, commented Dr. Alain Delpy, business development manager of Bened Biomedical.
Under this exclusive license agreement, this well-known South African health supplements firm will market products containing Bened’s world’s unique probiotic to increase serotonin and dopamine in the brain, PS128®. Hence, South Africans will soon be able to enjoy a natural way to be relieved from anxiety and depression.
The agreement will expand PS128® sales in South Africa, where the probiotic supplements market is expected to grow over 100% (+35 Million USD) by 2021, as well as having the potential to broaden business opportunities in the African continent.
